1. Home
  2. AGIO vs OPRA Comparison

AGIO vs OPRA Comparison

Compare AGIO & OPRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.62

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Opera Limited

OPRA

Opera Limited

HOLD

Current Price

$18.26

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
OPRA
Founded
2007
1996
Country
United States
Norway
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
AGIO
OPRA
Price
$33.62
$18.26
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$38.88
$21.50
AVG Volume (30 Days)
777.0K
370.8K
Earning Date
04-29-2026
04-28-2026
Dividend Yield
N/A
4.61%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,011,000.00
N/A
Revenue This Year
$76.75
$21.29
Revenue Next Year
$170.73
$15.34
P/E Ratio
N/A
$13.62
Revenue Growth
N/A
N/A
52 Week Low
$22.24
$11.71
52 Week High
$46.00
$21.06

Technical Indicators

Market Signals
Indicator
AGIO
OPRA
Relative Strength Index (RSI) 48.19 38.62
Support Level $32.54 $17.79
Resistance Level $36.04 $19.58
Average True Range (ATR) 1.28 0.58
MACD 0.10 -0.15
Stochastic Oscillator 42.77 20.19

Price Performance

Historical Comparison
AGIO
OPRA

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About OPRA Opera Limited

Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.

Share on Social Networks: